What Diorasis Therapeutics does

Diorasis Therapeutics is a pre-clinical stage privately held US biotech company developing a first-in-class disease-modifying gene therapy for open angle glaucoma (OAG), the leading cause of irreversible blindness worldwide. The company's core asset is an AAV vector that delivers an engineered enzymatically inactive tissue plasminogen activator (EI-tPA) variant to trabecular meshwork cells via a single intracameral injection, upregulating multiple matrix metalloproteinases (MMPs) to remodel extracellular matrix, restore aqueous humor outflow, and lower intraocular pressure (IOP) long-term — potentially for life. Critically, the therapy is gene-agnostic, meaning it is intended to be applicable to all OAG patients with elevated IOP regardless of genetic background, and it avoids lowering IOP in normal eyes, mitigating hypotony risk.

The company's scientific foundation is rooted in more than 20 years of award-winning glaucoma research conducted by co-founder John Danias at Mt. Sinai and SUNY, which established the role of the fibrinolytic pathway in outflow facility regulation. The asset is currently in IND-enabling safety and toxicology studies. The Scientific Advisory Board includes Dirk Sauer (33+ years pharma R&D), Kuldev Singh, Jeffrey Liebmann (clinical ophthalmology), and Alfred S. Lewin (gene therapy). Peer-reviewed publications in PLoS One, Experimental Eye Research, and Molecular Vision demonstrate decreased IOP in steroid-induced glaucoma models in mice and sheep.

The company has not yet commercialized any product, has no disclosed revenue, and operates on a pre-commercial biotech model. Its go-to-market strategy is expected to be partnership- or licensing-driven with major pharmaceutical companies for global commercialization, with possible direct commercialization to glaucoma specialists and ophthalmologists in select markets. The addressable market is large — approximately 2.7 million Americans and 57.5 million patients worldwide have open angle glaucoma, with the US spending approximately $2.86 billion annually on glaucoma care and 300,000 new US patients diagnosed each year. No external venture financing rounds, institutional investors, or parent company have been disclosed; ownership is founder-driven (Remis Bistras as CEO, John Danias, and Kali Stasi).

Name

Diorasis Therapeutics

Legal name

Diorasis Therapeutics Corporation

Website

https://diorasistherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Diorasis Therapeutics is a pre-clinical US biotech developing a first-in-class AAV gene therapy that delivers an engineered EI-tPA variant to the trabecular meshwork via a single intracameral injection to lower intraocular pressure long-term in open angle glaucoma patients.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Gene therapy
• Ophthalmic therapeutics
• Glaucoma treatment
• AAV vector delivery
• Biopharmaceutical research

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Gene Therapy Product Commercialization: Pre-clinical stage biotech company developing first-in-class disease-modifying gene therapy for open angle glaucoma. Revenue will be generated through commercialization of the lead compound upon regulatory approval, likely through partnering/licensing deals with major pharmaceutical companies or direct commercialization to ophthalmologists and glaucoma specialists.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Diorasis Therapeutics is developing a first-in-class, disease-modifying gene therapy for open angle glaucoma using an AAV vector to deliver an engineered EI-tPA variant via a single intracameral injection. The therapy targets the root cause of elevated intraocular pressure by restoring trabecular meshwork function through MMP modulation, with the intent of replacing chronic eye-drop regimens. The lead compound is intended for eventual out-licensing or partnership with major pharmaceutical companies following pre-clinical and clinical milestones.

Product overview

Diorasis Therapeutics is a pre-clinical stage biotech company developing a single first-in-class disease-modifying gene therapy product for open angle glaucoma. The lead compound is an AAV-delivered enzymatically-inactive tissue plasminogen activator (EI-tPA) variant administered via a single intracameral injection. The therapy targets the trabecular meshwork to improve outflow facility and decrease intraocular pressure long-term, potentially for life. The company is currently conducting IND-enabling safety and toxicology experiments.

Differentiator

Problem solved

Functional benefit

Products and services

• EI-tPA AAV Gene Therapy for Open Angle Glaucoma

Quantifiable outcome

• Single administration provides long-term (potentially life-long) IOP reduction
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Mt. Sinai (John Danias Lab)coreStrategic or Co-development PartnerResearch partnership based on more than 20 years of award-winning glaucoma research conducted in John Danias' laboratory at Mt. Sinai. This foundational research established the role of fibrinolytic pathway components including tPA in regulation of outflow facility and identified tissue plasminogen activator (tPA) as an important regulator of outflow facility.
• SUNYcoreStrategic or Co-development PartnerResearch collaboration with SUNY based on 20+ years of award-winning glaucoma research. The foundational science behind the company's gene therapy technology originated from research conducted at SUNY.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Adverum Biotechnologies: Clinical-stage AAV-based gene therapy company targeting ophthalmology (wet AMD, diabetic retinopathy). Directly comparable to Diorasis as a fellow AAV gene therapy developer focused on high-prevalence eye diseases with single-injection profiles.
• REGENXBIO: Leading AAV gene therapy platform company with multiple ophthalmology programs (wet AMD, diabetic retinopathy). Comparable as an AAV-based gene therapy developer in ophthalmology with a similar scientific and regulatory pathway.
• 4D Molecular Therapeutics: Clinical-stage gene therapy company with ophthalmology programs (choroideremia, wet AMD) using engineered AAV capsids. Comparable therapeutic modality (single-dose AAV gene therapy) and target disease space (irreversible vision loss).
• MeiraGTx: Clinical-stage gene therapy company with multiple ophthalmology programs including X-linked retinitis pigmentosa and achromatopsia. Comparable as a single-asset/single-indication gene therapy developer in inherited and acquired eye diseases.
• Gyroscope Therapeutics: Was a clinical-stage gene therapy company developing GT005 for geographic atrophy AMD (acquired by Novartis in 2021 for $1.5B). Direct comparable for an ocular gene therapy company whose strategic value was recognized through major pharma acquisition.
• Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal diseases (RP, Stargardt). Comparable single-injection ocular gene therapy approach with focus on common, irreversible blinding conditions.
• Applied Genetic Technologies Corporation (AGTC): Clinical-stage AAV gene therapy company developing treatments for inherited retinal diseases (X-linked retinitis pigmentosa, achromatopsia). Comparable scientific platform and therapeutic area focus.

Emerging players

• Ocugen: Clinical-stage gene therapy and biologics company with ophthalmology programs targeting wet AMD and other retinal diseases. Comparable as a fellow emerging ocular gene therapy developer with a focus on partnership-driven commercialization.

Broad incumbents

• Aerie Pharmaceuticals: Was a commercial-stage glaucoma-focused pharmaceutical company (acquired by Alcon for $770M in 2020) with several approved IOP-lowering products. Comparable as a glaucoma-focused company, though operating in pharmacological rather than gene therapy modality.
• Spark Therapeutics: Pioneer in ocular gene therapy (developer of Luxturna for RPE65-mediated inherited retinal disease, acquired by Roche for $4.8B in 2019). Sets the benchmark for ophthalmic gene therapy commercialization, regulatory pathway, and strategic value.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/diorasis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diorasis Therapeutics